Assessing the reporting quality of pediatric neuro-oncology protocols, abstracts, and trials: Adherence to the SPIRIT and CONSORT statements.

CONSORT CONSORT-A SPIRIT clinical trial

Journal

Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528

Informations de publication

Date de publication:
Oct 2024
Historique:
medline: 16 9 2024
pubmed: 16 9 2024
entrez: 16 9 2024
Statut: epublish

Résumé

It is of vital importance to comprehensively and transparently report clinical trial activity. The SPIRIT 2013 and CONSORT 2010 statements exist to define items to be reported in clinical trial protocols and randomized controlled trials, respectively. The aim of this methodological review was to assess the reporting quality of pediatric neuro-oncology trial protocols and trial result articles. Published trial protocols and phase II/III trial result articles relating to pediatric brain tumors (published after the introduction of the SPIRIT 2013 statement), were identified through searches of 4 electronic bibliographic databases. The reporting quality of included trial protocols and result articles was assessed against the aforementioned statements. In addition, the CONSORT-A checklist was used to assess the abstracts of trial result articles. Percentage adherence was calculated for each article. Nine trial protocols, 68 phase II trials, and 8 phase III trial result articles were included. Mean adherence of trial protocols to the SPIRIT statement was 76.8% ( The reporting quality of pediatric neuro-oncology trial protocols and trial result articles requires improvement, particularly in the areas of randomization and blinding. This is consistent with our previously published findings following similar assessment of reporting quality for adult neuro-oncology trial protocols and result articles.

Sections du résumé

Background UNASSIGNED
It is of vital importance to comprehensively and transparently report clinical trial activity. The SPIRIT 2013 and CONSORT 2010 statements exist to define items to be reported in clinical trial protocols and randomized controlled trials, respectively. The aim of this methodological review was to assess the reporting quality of pediatric neuro-oncology trial protocols and trial result articles.
Methods UNASSIGNED
Published trial protocols and phase II/III trial result articles relating to pediatric brain tumors (published after the introduction of the SPIRIT 2013 statement), were identified through searches of 4 electronic bibliographic databases. The reporting quality of included trial protocols and result articles was assessed against the aforementioned statements. In addition, the CONSORT-A checklist was used to assess the abstracts of trial result articles. Percentage adherence was calculated for each article.
Results UNASSIGNED
Nine trial protocols, 68 phase II trials, and 8 phase III trial result articles were included. Mean adherence of trial protocols to the SPIRIT statement was 76.8% (
Conclusions UNASSIGNED
The reporting quality of pediatric neuro-oncology trial protocols and trial result articles requires improvement, particularly in the areas of randomization and blinding. This is consistent with our previously published findings following similar assessment of reporting quality for adult neuro-oncology trial protocols and result articles.

Identifiants

pubmed: 39279769
doi: 10.1093/nop/npae042
pii: npae042
pmc: PMC11398948
doi:

Types de publication

Journal Article

Langues

eng

Pagination

617-632

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Déclaration de conflit d'intérêts

All authors declare no conflict of interest. No authors have any personal or institutional financial interests related to any content of this manuscript.

Auteurs

Joshua S Suppree (JS)

School of Medicine, University of Liverpool, Liverpool, UK.
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.

Sophia Hart (S)

Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.

Sumirat M Keshwara (SM)

Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.

Sandhya Trichinopoly Krishna (S)

Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.

Conor S Gillespie (CS)

School of Medicine, University of Liverpool, Liverpool, UK.
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.

George E Richardson (GE)

School of Medicine, University of Liverpool, Liverpool, UK.
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.

Mohammad A Mustafa (MA)

Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.

Conor L Mallucci (CL)

Department of Pediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Barry Pizer (B)

University of Liverpool, Liverpool, UK.
Department of Pediatric Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

James Hayden (J)

Department of Pediatric Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Abdurrahman I Islim (AI)

Department of Pharmacology & Therapeutics, Institute of Systems, Molecular, & Integrative Biology, University of Liverpool, Liverpool, UK.
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.
Department of Pediatric Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Michael D Jenkinson (MD)

Department of Pharmacology & Therapeutics, Institute of Systems, Molecular, & Integrative Biology, University of Liverpool, Liverpool, UK.
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.
Department of Pediatric Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Christopher P Millward (CP)

Department of Pharmacology & Therapeutics, Institute of Systems, Molecular, & Integrative Biology, University of Liverpool, Liverpool, UK.
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.

Classifications MeSH